PT-141 vs Hexarelin
A comprehensive, data-driven comparison of PT-141 (Bremelanotide) and Hexarelin (Examorelin). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | PT-141 Bremelanotide, Vyleesi | Hexarelin Examorelin |
|---|---|---|
| FDA Status | FDA Approved | Not submitted |
| Category | Sexual Health | Growth Hormone |
| Primary Use | Hypoactive sexual desire disorder (HSDD) in women | Growth hormone optimization and cardiac protection |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $800 - $1,200/mo | $40 - $80/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1.75mg as needed, at least 45 min before activity | 100-200mcg 2x daily (pulsed use recommended) |
| Frequency | As needed | Daily |
| Mechanism | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal | Potent growth hormone secretagogue with cardioprotective properties beyond GH stimulation |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1PT-141 is FDA-approved, while Hexarelin is currently not submitted.
- 2Hexarelin is generally more affordable ($40 - $80/mo) compared to PT-141 ($800 - $1,200/mo).
- 3PT-141 is dosed as needed, while Hexarelin is daily.
- 4PT-141 has high-quality evidence, while Hexarelin has emerging-quality evidence.
- 5They belong to different categories: PT-141 (Sexual Health) vs Hexarelin (Growth Hormone).
Which Is Better For...
PT-141
Those seeking an FDA-approved treatment with established safety data
Hexarelin
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
PT-141
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
| Hexarelin | $40 - $80/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. Hexarelin works via Potent growth hormone secretagogue with cardioprotective properties beyond GH stimulation. They differ in FDA approval status, efficacy data, and cost.
PT-141 typically costs $800 - $1,200/mo, while Hexarelin costs $40 - $80/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
PT-141 is FDA-approved. Hexarelin is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Common side effects of Hexarelin include Increased appetite, Cortisol elevation, Prolactin elevation. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideHexarelin is a synthetic hexapeptide GH secretagogue that is significantly more potent than GHRP-6. Beyond stimulating growth hormone release, research has revealed unique cardioprotective effects ind...
View Full Hexarelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between PT-141 and Hexarelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.